Concepedia

Patricia Lorenzini

PL

Statistics

Publications

9

Citations

1.4K

H-Index

9

Active since

2020

Affiliations

Yonsei University(Current)

Janssen (United States)

National Cancer Center

Virginia Cancer Specialists

Providence Portland Medical Center

Patricia Lorenzini is an author at Yonsei University specializing in cancer pharmacology, oncology, and pharmacology.

Publications per year

2020–2025

9

Publications

9

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Keunchil Park, Eric B. Haura, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2021 · 632 citations · Full text

, , +17

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Byoung Chul Cho, Shun Lu, Enriqueta Felip et al. · New England Journal of Medicine · 2024 · 375 citations · Full text

, , +14

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim et al. · Journal of Clinical Oncology · 2024 · 114 citations · Full text

, , +16

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Byoung Chul Cho, Dong‐Wan Kim, Alexander I. Spira et al. · Nature Medicine · 2023 · 101 citations · Full text

, , +16

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).

Keunchil Park, Thomas John, Sang‐We Kim et al. · Journal of Clinical Oncology · 2020 · 67 citations

, , +17

1–5 of 9